Etybenzatropine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 32: | Line 32: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Etybenzatropine''' ([[International Nonproprietary Name|INN]]), also known as '''ethybenztropine''' ([[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) and '''tropethydrylin''', is an [[anticholinergic]]/[[antihistamine]] marketed under the [[trade name]]s '''Panolid''', '''Ponalid''', and '''Ponalide''', which is used as an [[antiparkinsonian agent]]. Like its [[analogue_(chemistry)|analogue]] [[benzatropine]], it may act as a [[dopamine reuptake inhibitor]].{{Citation needed|date=June 2011}} | '''Etybenzatropine''' ([[International Nonproprietary Name|INN]]), also known as '''ethybenztropine''' ([[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) and '''tropethydrylin''', is an [[anticholinergic]]/[[antihistamine]] marketed under the [[trade name]]s '''Panolid''', '''Ponalid''', and '''Ponalide''', which is used as an [[antiparkinsonian agent]]. Like its [[analogue_(chemistry)|analogue]] [[benzatropine]], it may act as a [[dopamine reuptake inhibitor]].{{Citation needed|date=June 2011}} | ||
| Line 45: | Line 42: | ||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Antiparkinsonian agents]] | [[Category:Antiparkinsonian agents]] | ||
Latest revision as of 20:45, 10 April 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, IM, IV |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H27NO |
| Molar mass | 321.456 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Etybenzatropine |
|
Articles |
|---|
|
Most recent articles on Etybenzatropine Most cited articles on Etybenzatropine |
|
Media |
|
Powerpoint slides on Etybenzatropine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Etybenzatropine at Clinical Trials.gov Trial results on Etybenzatropine Clinical Trials on Etybenzatropine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Etybenzatropine NICE Guidance on Etybenzatropine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Etybenzatropine Discussion groups on Etybenzatropine Patient Handouts on Etybenzatropine Directions to Hospitals Treating Etybenzatropine Risk calculators and risk factors for Etybenzatropine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Etybenzatropine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Etybenzatropine (INN), also known as ethybenztropine (USAN, BAN) and tropethydrylin, is an anticholinergic/antihistamine marketed under the trade names Panolid, Ponalid, and Ponalide, which is used as an antiparkinsonian agent. Like its analogue benzatropine, it may act as a dopamine reuptake inhibitor.[citation needed]
See also
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- All articles with unsourced statements
- Articles with unsourced statements from June 2011
- Articles with invalid date parameter in template
- Antiparkinsonian agents
- Muscarinic antagonists
- Tropanes
- Ethers
- Drug